Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Haemonetics (HAE) Shares Outstanding (2016 - 2025)

Haemonetics has reported Shares Outstanding over the past 16 years, most recently at $46.8 million for Q4 2025.

  • For Q4 2025, Shares Outstanding fell 6.78% year-over-year to $46.8 million; the TTM value through Dec 2025 reached $46.8 million, down 6.78%, while the annual FY2025 figure was $48.2 million, 5.06% down from the prior year.
  • Shares Outstanding for Q4 2025 was $46.8 million at Haemonetics, roughly flat from $46.7 million in the prior quarter.
  • Over five years, Shares Outstanding peaked at $51.3 million in Q3 2022 and troughed at $46.7 million in Q3 2025.
  • A 5-year average of $50.1 million and a median of $50.7 million in 2023 define the central range for Shares Outstanding.
  • Biggest five-year swings in Shares Outstanding: rose 1.08% in 2021 and later decreased 7.21% in 2025.
  • Year by year, Shares Outstanding stood at $51.1 million in 2021, then decreased by 1.21% to $50.4 million in 2022, then grew by 0.68% to $50.8 million in 2023, then dropped by 1.08% to $50.2 million in 2024, then dropped by 6.78% to $46.8 million in 2025.
  • Business Quant data shows Shares Outstanding for HAE at $46.8 million in Q4 2025, $46.7 million in Q3 2025, and $48.2 million in Q2 2025.